Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.
Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.